Newsfeed : Study: New Myriad Inc. HIV Drug Can Reduce Viral Load 50-fold in 2 Weeks

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Newsfeed » September 2009

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


September 15, 2009

Study: New Myriad Inc. HIV Drug Can Reduce Viral Load 50-fold in 2 Weeks

Myriad Pharmaceuticals Inc.’s experimental HIV drug, bevirimat dimeglumine, can reduce viral load by as much as 50-fold in two weeks in some patients, according to a new study reported by Bloomberg. Researchers presented their findings September 14 at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

Bevirimat is in a new class of HIV drugs called maturation inhibitors, which prevent the virus from growing into a form capable of infecting other healthy cells. During the study, 32 Australian men took one of two doses of bevirimat two times a day for two weeks.

Among the 26 patients who were new to HIV treatment and received the highest dose of the drug, viral load declined an average of more than 20-fold and as much as 50-fold. Overall, the drug reduced the virus 6-fold on average.

In July, Myriad said it next planned to begin a 24-week study of the drug this year.

Search: Myriad Pharmaceuticals, bevirimat dimeglumine, Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC, maturation inhibitors

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.